sb 203580 has been researched along with bi 2536 in 5 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (bi 2536) | Trials (bi 2536) | Recent Studies (post-2010) (bi 2536) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 193 | 13 | 169 |
| Protein | Taxonomy | sb 203580 (IC50) | bi 2536 (IC50) |
|---|---|---|---|
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.1211 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.0593 | |
| Transcription initiation factor TFIID subunit 1 | Homo sapiens (human) | 0.16 | |
| Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | 0.0549 | |
| Bromodomain testis-specific protein | Homo sapiens (human) | 0.83 | |
| Serine/threonine-protein kinase PLK3 | Homo sapiens (human) | 0.0148 | |
| Serine/threonine-protein kinase PLK2 | Homo sapiens (human) | 0.0123 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.408 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Munoz, L | 1 |
| Ayoub, AM; Berndt, N; Carlson, AS; Cui, H; Divakaran, A; Harki, DA; Mishra, NK; Pomerantz, WCK; Schonbrunn, EK; Talluri, SK; Topczewski, JJ; Widen, JC; Zhu, JY | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
1 review(s) available for sb 203580 and bi 2536
| Article | Year |
|---|---|
Non-kinase targets of protein kinase inhibitors.
Topics: Animals; Drug Design; Drug Evaluation, Preclinical; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Kinases | 2017 |
4 other study(ies) available for sb 203580 and bi 2536
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.
Topics: A549 Cells; Humans; Imidazoles; p38 Mitogen-Activated Protein Kinases; Protein Domains; Protein Kinase Inhibitors; Water | 2018 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |